Symbols / ENSC Stock $0.50 -14.08% Ensysce Biosciences, Inc.
ENSC (Stock) Chart
About
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.59M |
| Enterprise Value | 259.90K | Income | -10.18M | Sales | 5.07M |
| Book/sh | 0.70 | Cash/sh | 0.47 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -0.22 | PEG | — |
| P/S | 0.91 | P/B | 0.71 | P/C | — |
| EV/EBITDA | -0.03 | EV/Sales | 0.05 | Quick Ratio | 1.04 |
| Current Ratio | 1.59 | Debt/Eq | 10.63 | LT Debt/Eq | — |
| EPS (ttm) | -3.98 | EPS next Y | -2.23 | EPS Growth | — |
| Revenue Growth | 44.40% | Earnings | 2026-03-30 17:00 | ROA | -98.10% |
| ROE | -3.25% | ROIC | — | Gross Margin | -104.81% |
| Oper. Margin | -147.79% | Profit Margin | -200.84% | Shs Outstand | 9.28M |
| Shs Float | 9.25M | Short Float | 3.67% | Short Ratio | 0.01 |
| Short Interest | — | 52W High | 4.85 | 52W Low | 0.31 |
| Beta | 1.14 | Avg Volume | 6.22M | Volume | 289.28K |
| Target Price | $16.45 | Recom | Strong_buy | Prev Close | $0.58 |
| Price | $0.49 | Change | -14.08% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.45
Mean price target
2. Current target
$0.50
Latest analyst target
3. DCF / Fair value
$-8.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.50
Low
$16.45
High
$16.45
Mean
$16.45
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-09-25 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-07-03 | init | HC Wainwright & Co. | — → Buy | $9 |
- Pain drug developer pulls another $2M for overdose-resistant treatments - Stock Titan ue, 07 Apr 2026 12
- Ensysce Raises $2 Million in Private Placement of Series B Preferred and Warrants - TradingView Wed, 08 Apr 2026 10
- Ensysce Biosciences Secures $2 Million Private Financing - TipRanks Wed, 08 Apr 2026 11
- ENSC Should I Buy - Intellectia AI Fri, 03 Apr 2026 07
- Ensysce Biosciences (NASDAQ: ENSC) closes $2M preferred and warrant deal - Stock Titan Wed, 08 Apr 2026 10
- Rally Mode: Can ENSC sustain earnings growth - Forecast Cut & Precise Swing Trade Entry Alerts - baoquankhu1.vn hu, 09 Apr 2026 03
- Ensysce Biosciences Announces Board Member Curtis Rosebraugh Resignation - TipRanks Fri, 03 Apr 2026 20
- Ensysce Biosciences (ENSC) files correction to Series B preferred stock - Stock Titan Mon, 23 Mar 2026 07
- CEO takes live questions on Ensysce PF614 pain-drug plans - Stock Titan Wed, 04 Mar 2026 08
- If You Invested $1,000 in Ensysce Biosciences Inc (ENSC) - Stock Titan Mon, 23 Mar 2026 02
- Board member Curtis Rosebraugh exits Ensysce Biosciences (NASDAQ: ENSC) - Stock Titan Fri, 03 Apr 2026 20
- Opioid designed to stay inactive until swallowed hits Phase 3 milestone - Stock Titan Wed, 28 Jan 2026 08
- New opioid design limits drug release when too many pills are swallowed - Stock Titan ue, 03 Mar 2026 08
- Opioid safety drug developer Ensysce explores deals, possible asset sales - Stock Titan Wed, 25 Feb 2026 08
- Ensysce pushes abuse-deterrent opioid into late-stage testing - Stock Titan Mon, 30 Mar 2026 20
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
10.24
+52.17%
|
6.73
-37.21%
|
10.72
-55.75%
|
24.22
|
| Research And Development |
|
10.38
+43.74%
|
7.22
-4.85%
|
7.59
-61.75%
|
19.84
|
| Selling General And Administration |
|
4.93
+4.45%
|
4.72
-11.95%
|
5.36
-22.41%
|
6.91
|
| General And Administrative Expense |
|
4.93
+4.45%
|
4.72
-11.95%
|
5.36
-22.41%
|
6.91
|
| Other Gand A |
|
4.93
+4.45%
|
4.72
-11.95%
|
5.36
-22.41%
|
6.91
|
| Other Operating Expenses |
|
-5.07
+2.75%
|
-5.21
-133.58%
|
-2.23
+11.61%
|
-2.52
|
| Total Expenses |
|
10.24
+52.17%
|
6.73
-37.21%
|
10.72
-55.75%
|
24.22
|
| Operating Income |
|
-10.24
-52.17%
|
-6.73
+37.21%
|
-10.72
+55.75%
|
-24.22
|
| Total Operating Income As Reported |
|
-10.24
-52.17%
|
-6.73
+37.21%
|
-10.72
+55.75%
|
-24.22
|
| EBITDA |
|
-10.15
-51.58%
|
-6.70
+34.81%
|
-10.27
+57.37%
|
-24.10
|
| Normalized EBITDA |
|
-10.15
-51.58%
|
-6.70
+34.81%
|
-10.27
+57.37%
|
-24.10
|
| Reconciled Depreciation |
|
0.01
|
0.00
|
—
|
0.00
|
| EBIT |
|
-10.16
-51.68%
|
-6.70
+34.81%
|
-10.27
+57.37%
|
-24.10
|
| Total Unusual Items |
|
—
|
—
|
0.43
-92.52%
|
5.76
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.43
-92.52%
|
5.76
|
| Special Income Charges |
|
—
|
—
|
0.15
-91.83%
|
1.79
|
| Other Special Charges |
|
—
|
—
|
-0.15
+91.83%
|
-1.79
|
| Net Income |
|
-10.18
-27.40%
|
-7.99
+24.74%
|
-10.61
+56.09%
|
-24.17
|
| Pretax Income |
|
-10.18
-27.41%
|
-7.99
+24.84%
|
-10.63
+56.10%
|
-24.21
|
| Net Non Operating Interest Income Expense |
|
-0.02
+98.55%
|
-1.29
-264.59%
|
-0.35
+92.90%
|
-4.98
|
| Interest Expense Non Operating |
|
0.02
-98.55%
|
1.29
+264.59%
|
0.35
+223.16%
|
0.11
|
| Net Interest Income |
|
-0.02
+98.55%
|
-1.29
-264.59%
|
-0.35
+92.90%
|
-4.98
|
| Interest Expense |
|
0.02
-98.55%
|
1.29
+264.59%
|
0.35
+223.16%
|
0.11
|
| Other Income Expense |
|
0.08
+148.82%
|
0.03
-92.47%
|
0.45
-91.08%
|
5.00
|
| Other Non Operating Income Expenses |
|
0.08
+148.82%
|
0.03
-92.47%
|
0.45
-91.08%
|
5.00
|
| Gain On Sale Of Security |
|
—
|
—
|
0.28
-95.07%
|
5.76
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-10.18
-27.41%
|
-7.99
+24.84%
|
-10.63
+56.10%
|
-24.21
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.18
-27.40%
|
-7.99
+24.74%
|
-10.61
+56.09%
|
-24.17
|
| Net Income From Continuing And Discontinued Operation |
|
-10.18
-27.40%
|
-7.99
+24.74%
|
-10.61
+56.09%
|
-24.17
|
| Net Income Continuous Operations |
|
-10.18
-27.41%
|
-7.99
+24.84%
|
-10.63
+56.10%
|
-24.21
|
| Minority Interests |
|
0.00
+558.11%
|
0.00
-99.44%
|
0.01
-62.70%
|
0.04
|
| Normalized Income |
|
-10.18
-27.40%
|
-7.99
+24.74%
|
-10.61
+56.09%
|
-24.17
|
| Net Income Common Stockholders |
|
-10.18
-27.40%
|
-7.99
+24.83%
|
-10.63
+57.64%
|
-25.09
|
| Otherunder Preferred Stock Dividend |
|
0.00
-100.00%
|
0.00
-97.76%
|
0.01
-98.58%
|
0.91
|
| Diluted EPS |
|
-3.98
+65.24%
|
-11.45
+83.74%
|
-70.40
+96.63%
|
-2,091.60
|
| Basic EPS |
|
-3.98
+65.24%
|
-11.45
+83.74%
|
-70.40
+96.63%
|
-2,091.60
|
| Basic Average Shares |
|
2.56
+88.58%
|
1.36
+798.24%
|
0.15
+323.59%
|
0.04
|
| Diluted Average Shares |
|
2.56
+88.58%
|
1.36
+798.24%
|
0.15
+323.59%
|
0.04
|
| Diluted NI Availto Com Stockholders |
|
-10.18
-27.40%
|
-7.99
+24.83%
|
-10.63
+57.64%
|
-25.09
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
4.88
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets |
|
5.60
+106.69%
|
2.71
|
| Current Assets |
|
5.34
+133.51%
|
2.29
|
| Cash Cash Equivalents And Short Term Investments |
|
3.50
+211.68%
|
1.12
|
| Cash And Cash Equivalents |
|
3.50
+211.68%
|
1.12
|
| Receivables |
|
0.12
+27.22%
|
0.10
|
| Other Receivables |
|
0.12
+27.22%
|
0.10
|
| Prepaid Assets |
|
1.70
+62.00%
|
1.05
|
| Other Current Assets |
|
0.02
+0.00%
|
0.02
|
| Total Non Current Assets |
|
0.25
-39.76%
|
0.42
|
| Net PPE |
|
0.00
|
0.00
|
| Other Non Current Assets |
|
0.25
-39.76%
|
0.42
|
| Total Liabilities Net Minority Interest |
|
2.22
-34.00%
|
3.36
|
| Current Liabilities |
|
2.21
-33.78%
|
3.33
|
| Payables And Accrued Expenses |
|
1.91
-23.11%
|
2.48
|
| Payables |
|
1.36
-29.90%
|
1.94
|
| Accounts Payable |
|
1.36
-29.90%
|
1.94
|
| Current Accrued Expenses |
|
0.55
+1.14%
|
0.54
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.30
-64.71%
|
0.85
|
| Current Debt |
|
0.30
-64.71%
|
0.85
|
| Other Current Borrowings |
|
0.30
-64.71%
|
0.85
|
| Current Capital Lease Obligation |
|
—
|
0.00
|
| Current Deferred Liabilities |
|
—
|
—
|
| Current Deferred Revenue |
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.01
-61.74%
|
0.03
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
| Long Term Debt |
|
—
|
—
|
| Other Non Current Liabilities |
|
—
|
—
|
| Stockholders Equity |
|
3.71
+1248.62%
|
-0.32
|
| Common Stock Equity |
|
3.71
+1248.62%
|
-0.32
|
| Capital Stock |
|
0.00
+547.62%
|
0.00
|
| Common Stock |
|
0.00
+547.62%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
| Share Issued |
|
1.36
+546.40%
|
0.21
|
| Ordinary Shares Number |
|
1.36
+546.41%
|
0.21
|
| Treasury Shares Number |
|
0.00
+20.00%
|
0.00
|
| Additional Paid In Capital |
|
133.25
+9.91%
|
121.23
|
| Retained Earnings |
|
-129.54
-6.57%
|
-121.56
|
| Minority Interest |
|
-0.33
-0.02%
|
-0.33
|
| Total Equity Gross Minority Interest |
|
3.38
+618.98%
|
-0.65
|
| Total Capitalization |
|
3.71
+1248.62%
|
-0.32
|
| Working Capital |
|
3.14
+400.50%
|
-1.04
|
| Invested Capital |
|
4.01
+654.00%
|
0.53
|
| Total Debt |
|
0.30
-64.71%
|
0.85
|
| Net Debt |
|
—
|
—
|
| Capital Lease Obligations |
|
—
|
0.00
|
| Net Tangible Assets |
|
3.71
+1248.62%
|
-0.32
|
| Tangible Book Value |
|
3.71
+1248.62%
|
-0.32
|
| Derivative Product Liabilities |
|
0.01
-61.74%
|
0.03
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.81
-4.05%
|
-7.50
+30.40%
|
-10.78
+39.73%
|
-17.89
|
| Cash Flow From Continuing Operating Activities |
|
-7.81
-4.05%
|
-7.50
+30.40%
|
-10.78
+39.73%
|
-17.89
|
| Net Income From Continuing Operations |
|
-10.18
-27.41%
|
-7.99
+24.84%
|
-10.63
+56.10%
|
-24.21
|
| Depreciation Amortization Depletion |
|
0.01
|
0.00
|
—
|
0.00
|
| Depreciation |
|
0.01
|
0.00
|
—
|
0.00
|
| Depreciation And Amortization |
|
0.01
|
0.00
|
—
|
0.00
|
| Other Non Cash Items |
|
0.68
-45.12%
|
1.24
+260.11%
|
0.34
-95.84%
|
8.29
|
| Stock Based Compensation |
|
0.18
+59.94%
|
0.11
-87.41%
|
0.88
-17.98%
|
1.07
|
| Operating Gains Losses |
|
-0.01
+38.03%
|
-0.02
+94.26%
|
-0.28
+95.78%
|
-6.74
|
| Gain Loss On Investment Securities |
|
-0.01
+38.03%
|
-0.02
+94.26%
|
-0.28
+95.78%
|
-6.73
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
0.00
+100.00%
|
-0.15
+91.83%
|
-1.79
|
| Change In Working Capital |
|
1.52
+278.01%
|
-0.85
+10.12%
|
-0.95
-117.28%
|
5.48
|
| Change In Receivables |
|
-0.30
-1015.58%
|
-0.03
-114.81%
|
0.18
+8.71%
|
0.16
|
| Change In Prepaid Assets |
|
-0.44
-74.06%
|
-0.25
-118.10%
|
1.39
-15.77%
|
1.65
|
| Change In Payables And Accrued Expense |
|
2.25
+492.87%
|
-0.57
+77.26%
|
-2.52
-168.73%
|
3.66
|
| Change In Accrued Expense |
|
0.43
+6909.26%
|
0.01
+100.48%
|
-1.28
-225.72%
|
1.02
|
| Change In Payable |
|
1.82
+413.62%
|
-0.58
+53.10%
|
-1.23
-146.71%
|
2.64
|
| Change In Account Payable |
|
1.82
+413.62%
|
-0.58
+53.10%
|
-1.23
-146.71%
|
2.64
|
| Investing Cash Flow |
|
-0.12
|
0.00
|
0.00
-100.00%
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
-0.12
|
0.00
|
0.00
-100.00%
|
0.00
|
| Net PPE Purchase And Sale |
|
-0.12
|
0.00
|
—
|
—
|
| Purchase Of PPE |
|
-0.12
|
0.00
|
—
|
—
|
| Capital Expenditure |
|
-0.12
|
—
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
8.74
-11.57%
|
9.88
+12.85%
|
8.76
-0.11%
|
8.77
|
| Cash Flow From Continuing Financing Activities |
|
8.74
-11.57%
|
9.88
+12.85%
|
8.76
-0.11%
|
8.77
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-0.49
-180.14%
|
0.61
-90.12%
|
6.13
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
1.61
-78.69%
|
7.53
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.49
+51.49%
|
-1.00
+28.98%
|
-1.41
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
1.61
-78.69%
|
7.53
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-0.49
+51.49%
|
-1.00
+28.98%
|
-1.41
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-0.49
-180.14%
|
0.61
-90.12%
|
6.13
|
| Net Common Stock Issuance |
|
1.10
-34.13%
|
1.67
-81.55%
|
9.05
+139.21%
|
3.78
|
| Proceeds From Stock Option Exercised |
|
4.77
-54.71%
|
10.54
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
-1.11
+39.76%
|
-1.84
-104.62%
|
-0.90
+21.29%
|
-1.14
|
| Changes In Cash |
|
0.81
-66.02%
|
2.38
+217.51%
|
-2.02
+77.80%
|
-9.12
|
| Beginning Cash Position |
|
3.50
+211.68%
|
1.12
-64.30%
|
3.15
-74.34%
|
12.26
|
| End Cash Position |
|
4.31
+23.08%
|
3.50
+211.68%
|
1.12
-64.30%
|
3.15
|
| Free Cash Flow |
|
-7.93
-5.69%
|
-7.50
+30.40%
|
-10.78
+39.73%
|
-17.89
|
| Income Tax Paid Supplemental Data |
|
0.00
-21.88%
|
0.00
+0.00%
|
0.00
+100.00%
|
0.00
|
| Common Stock Issuance |
|
1.10
-34.13%
|
1.67
-81.55%
|
9.05
+139.21%
|
3.78
|
| Issuance Of Capital Stock |
|
5.08
+203.89%
|
1.67
-81.55%
|
9.05
+139.21%
|
3.78
|
| Net Preferred Stock Issuance |
|
3.98
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
3.98
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-08 View
- 8-K2026-04-03 View
- 10-K2026-03-30 View
- 8-K2026-03-30 View
- 8-K2026-03-30 View
- 8-K2026-03-23 View
- 8-K2026-02-27 View
- 8-K2026-01-08 View
- 8-K2025-11-17 View
- 10-Q2025-11-14 View
- 8-K2025-11-14 View
- 10-Q2025-08-13 View
- 8-K2025-08-13 View
- 8-K2025-06-05 View
- 10-Q2025-05-13 View
- 8-K2025-05-13 View
- 8-K2025-04-24 View
- 8-K2025-04-01 View
- 8-K2025-03-31 View
- 10-K2025-03-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|